Dogwood Therapeutics is a development-stage biopharmaceutical company focused on creating non-opioid medicines to treat pain and neuropathy, particularly chemotherapy-induced peripheral neuropathy and other chronic pain conditions. The company's lead program, Halneuron, is a highly purified tetrodotoxin derivative that selectively modulates Nav1.7 sodium ion channels to suppress pain signal transmission, with additional pipeline programs including SP16, a synthetic anti-inflammatory peptide, and antiviral candidates targeting fibromyalgia and post-viral conditions. The company is pre-revenue and plans to commercialize its therapies through partnerships and sales agreements with pharmaceutical distributors to oncologists, anesthesiologists, and other specialists, while outsourcing manufacturing to third-party contractors and seeking regulatory approval for its lead and follow-on candidates.